IO Biotech, Inc.
IOBT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | -0.05 | 0.03 | -0.01 |
| FCF Yield | -76.04% | -21.67% | -32.17% | -32.40% |
| EV / EBITDA | 0.25 | -2.80 | -1.65 | -0.09 |
| Quality | ||||
| ROIC | -71.98% | -97.12% | -80.65% | -55.86% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 50.00% |
| Cash Conversion Ratio | 2.21 | 0.76 | 1.03 | 0.63 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 6.88% | 14.07% | -17.64% | 5.68% |
| Safety | ||||
| Net Debt / EBITDA | 1.51 | 0.77 | 1.60 | 2.17 |
| Interest Coverage | 21.85 | -91.58 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -2,129.62 | -2,060.88 | -867.07 |